Short Interest in enGene Holdings Inc. (NASDAQ:ENGNW) Decreases By 50.0%

enGene Holdings Inc. (NASDAQ:ENGNW) saw a large decline in short interest during the month of March. As of March 15th, there was short interest totalling 100 shares, a decline of 50.0% from the February 28th total of 200 shares. Based on an average trading volume of 9,700 shares, the short-interest ratio is presently 0.0 days.

enGene Stock Down 8.8 %

ENGNW stock traded down $0.06 during mid-day trading on Friday, hitting $0.62. The company had a trading volume of 4,254 shares, compared to its average volume of 12,850. The company has a 50-day moving average price of $0.82 and a 200 day moving average price of $1.23. enGene has a 12-month low of $0.42 and a 12-month high of $5.35.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.